AtriCure's stock surged 32.46% in pre-market trading on Thursday following the release of its preliminary 2025 results and optimistic 2026 guidance. The company projected revenues between US$600 million and US$610 million for 2026, alongside expectations of positive adjusted EBITDA, net income, and cash flow.

The positive outlook was further bolstered by the extension of AtriCure's asset-based revolving credit facility, which now offers improved terms and lower interest costs. This financial flexibility is expected to support the company's commercial efforts and clinical programs, including the completion of enrollment in a key clinical trial.